ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Imaging and Image-directed Interventions
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1662492
This article is part of the Research TopicPrecision Medical Imaging for Cancer Diagnosis and Treatment Volume IIIView all 3 articles
Diagnostic value of super-resolution ultrasound imaging in differentiating benign and malignant BI-RADS-4 breast lesions
Provisionally accepted- First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Benign and malignant breast tumors exhibit distinct microvascular morphological patterns and spatial distribution characteristics; however, current clinical imaging modalities cannot comprehensively assess their microvascular network architecture. Super-resolution ultrasound (SRUS) imaging addresses this critical gap by providing super-resolved visualization of microvascular topology. This study aimed to evaluate the utility of SRUS imaging in visualizing breast lesion microvasculature and establishing diagnostic models for BI-RADS 4 masses. Methods: A total of 120 breast lesions from 117 patients with conventional ultrasound-confirmed BI-RADS 4 lesions were prospectively enrolled in this study between July 2024 and January 2025. Preoperative conventional ultrasound and SRUS examinations were performed on all included patients. Based on pathological findings, the lesions were categorized as benign (n = 85) or malignant (n = 35). The benign group was further stratified into hypovascular (n = 42) and hypervascular (n = 43) subgroups based on the SRUS enhancement levels. Univariate analysis was performed to screen SRUS parameters, and variables with P < 0.05 were incorporated into multivariate logistic regression models to construct nomogram-based predictive models and validated using ROC analysis. Results: Max vel (OR = 1.848, 95% CI: 1.205–3.122), curvature (A/E) (OR = 2.162, 95% CI: 1.981–2.323), and complexity level (OR = 1.772, 95% CI: 1.608–1.942) independently predicted malignancy (all P < 0.05). Curvature (A/E) and complexity level were also independent markers for distinguishing malignant lesions from hypervascular benign lesions (curvature (A/E): OR = 1.808, 95% CI: 1.612– 1.987; complexity level: OR = 1.952, 95% CI: 1.804–2.181; both P < 0.05). The nomogram prediction models demonstrated high diagnostic efficacy, with AUC values of 0.899 (95% CI: 0.844– 0.953) (sensitivity = 94.3%, specificity = 76.5%) for benign compared to 0.816 (95% CI: 0.721– 0.910 (sensitivity = 65.1%, specificity = 88.6%) for malignant differentiation. The Hosmer-Lemeshow goodness-of-fit test indicated adequate model fit (all P > 0.05). The nomogram prediction model demonstrated superior net benefit in predicting breast cancer compared to alternative strategies. Conclusion: SRUS enables microvascular characterization of breast lesions, with validated nomograms demonstrating high diagnostic accuracy for early cancer detection.
Keywords: SRUS, BI-RADS 4 category, Breast lesions, nomogram, Prediction model
Received: 09 Jul 2025; Accepted: 22 Sep 2025.
Copyright: © 2025 HOU, LI, LIU, GAO and SONG. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Tao SONG, doctorsongtao@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.